Intranasal administration of milnacipran in rats: Evaluation of the transport of drugs to the systemic circulation and central nervous system and the pharmacological effect

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 5, 2011, Pages 740-747

  Uchida, Masaki ^a   Katoh, Takuya ^a   Mori, Mutsuhiro ^b   Maeno, Takuya ^c   Ohtake, Kazuo ^a   Kobayashi, Jun ^a   Morimoto, Yasunori ^a   Natsume, Hideshi ^a  

^a JOSAI UNIVERSITY   (Japan)

^b ASAHI KASEI PHARMA CORPORATION   (Japan)

^c National Hospital Organization   (Japan)

Author keywords

Central nervous systems; Chitosan; Forced swimming test; Intranasal administration; Milnacipran

Indexed keywords

CHITOSAN; MILNACIPRAN;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TRANSPORT; FORCED SWIMMING TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM; CYCLOPROPANES; MALE; RATS; RATS, WISTAR;

EID: 79955648704     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.740     Document Type: Article

References (37)

1. Kendell R. E., "Depressive Disorders," ed. by Maj M., Sartorius N., Second Edition, John Wiley & Sons Ltd., Chichester, West Sussex, 2002, pp. 52-54.
2. Slattery D. A., Hudson A. L., Nutt D. J., Fundam. Clin. Pharmacol., 18, 1-21 (2004).
3. Nestler E. J., Barrot M., DiLeone R. J., Eisch A. J., Gold S. J., Monteggia L. M., Neuron, 34, 13-25 (2002).
4. Cooper J. R., Floyd E. B., Roth R. H., "The Biochemical Basis of Neuropharmacology," 7th ed., Oxford University Press, New York, 1996, pp. 340-343.
5. Janicak P. G., Davis J. M., Preskorn S. H., Ayd F. J. Jr., "Principles and Practice of Psychopharmacotherapy," Third ed., Lippincott Williams & Wilkins, Philadelphia, 2001.
6. Delimi-Stula A., Hum. Psychopharmacol., 15, 255-260 (2000).
7. Komoroski R. A., Newton J. E., Cardwell D., Sprigg J., Pearce J., Karson C. N., Magn. Reson. Med., 31, 204-211 (1994).
8. Miyamoto M., Natsume H., Iwata S., Ohtake K., Yamaguchi M., Kobayashi D., Sugibayashi K., Yamashina M., Morimoto Y., Eur. J. Pharm. Biopharm., 52, 21-30 (2001).
9. Miyamoto M., Tsukune T., Hori S., Hayashi T., Natsume H., Sugibayashi K., Morimoto Y., Biopharm. Drug Dispos., 22, 137-146 (2001).
10. Miyamoto M., Natsume H., Satoh I., Ohtake K., Yamaguchi M., Kobayashi D., Sugibayashi K., Morimoto Y., Int. J. Pharm., 226, 127-138 (2001).
11. Charlton S. T., Jones N. S., Davis S. S., Illum L., Eur. J. Pharm. Sci., 30, 295-302 (2007).
12. Charlton S. T., Davis S. S., Illum L., J. Controlled Release, 118, 225-234 (2007).
13. Charlton S. T., Davis S. S., Illum L., Int. J. Pharm., 338, 94-103 (2007).
14. Pardridge W. M., Pharm. Sci. Technol. Today, 2, 49-59 (1999).
15. Illum L., Drug Discov. Today, 7, 1184-1189 (2002).
16. Illum L., J. Controlled Release, 87, 187-198 (2003).
17. Hilger P. A., "Otolaryngology, A Textbook of Ear, Nose and Throat Diseases," W. B. Saunders, Philadelphia, 1989, pp. 177-195.
18. Illum L., J. Pharm. Pharmacol., 56, 3-17 (2004).
19. Thorne R. G., Pronk G. J., Padmanabhan V., Frey W. H. II, Neuroscience, 127, 481-496 (2004).
20. Illum L., Pharm. Res., 15, 1326-1331 (1998).
21. Kumar M. N., Muzzarelli R. A., Muzzarelli C., Sashiwa H., Domb A. J., Chem. Rev., 104, 6017-6084 (2004).
22. Varum K. M., Myhr M. M., Hjerde R. J., Smidsrod O., Carbohydr. Res., 299, 99-101 (1997).
23. Rao S. B., Sharma C. P., J. Biomed. Mater. Res., 34, 21-28 (1997).
24. Alonso M. J., Sanchez A., J. Pharm. Pharmacol., 55, 1451-1463 (2003).
25. Lee K. Y., Macromol. Res., 15, 195-201 (2007).
26. Illum L., Eur. J. Pharm. Sci., 11, 1-18 (2000).
27. Smith J. M., Dornich M., Wood E. J., Biomaterials, 26, 3269-3276 (2004).
28. Hirai S., Yashiki T., Miwa H., Int. J. Pharm., 9, 165-172 (1981).
29. Porsolt R. D., Le Pichon M., Jalfre M., Nature (London), 266, 730-732 (1977).
30. Chou R. C., Levy G., J. Pharmacol. Exp. Ther., 219, 42-48 (1981).
31. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacobio-Dyn., 4, 879-885 (1981).
32. Van der Berg M. P., Merkus P., Romeijn S. G., Verhoef J. C., Merkus F. W. H. M., J. Drug Target, 11, 325-331 (2003).
33. Charlton S. T., Whetstone J., Fayinka S. T., Read K. D., Illum L., Davis S. S., Pharm. Res., 25, 1531-1543 (2008).
34. Sakane T., Akizuki M., Yamashita S., Nadai T., Hashida M., Sezaki H., Chem. Pharm. Bull., 39, 2456-2458 (1991).
35. Sakane T., Akizuki M., Yamashita S., Sezaki H., Nadai T., J. Pharm. Pharmacol., 46, 378-379 (1994).
36. Sakane T., Akizuki M., Taki Y., Yamashita S., Sezaki H., Nadai T., J. Pharm. Pharmacol., 47, 379-381 (1995).
37. Soane R. J., Hinchcliffe M., Davis S. S., Illum L., Int. J. Pharm., 217, 183-191 (2001).